Treatments in the pipeline for attention-deficit/hyperactivity disorder (ADHD) in adults
-
Published:2024-08
Issue:
Volume:163
Page:105774
-
ISSN:0149-7634
-
Container-title:Neuroscience & Biobehavioral Reviews
-
language:en
-
Short-container-title:Neuroscience & Biobehavioral Reviews
Author:
Veronesi Guilherme Fusetto,
Gabellone Alessandra,
Tomlinson Anneka,
Solmi Marco,
Correll Christoph U.,
Cortese SamueleORCID
Reference46 articles.
1. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial;Adler;Int Clin. Psychopharmacol.,2021
2. Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials;Adler;J. Clin. Psychopharmacol.,2022
3. Associations between mental and physical conditions in children and adolescents: An umbrella review;Arrondo;Neurosci. Biobehav Rev.,2022
4. Prevalence of attention deficit hyperactivity disorder in adults: Umbrella review of evidence generated across the globe;Ayano;Psychiatry Res,2023
5. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study;Biederman;J. Psychopharmacol.,2019